Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
about
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseUse of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Combination therapy for inflammatory bowel diseaseClinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.Second Korean guidelines for the management of Crohn's disease.Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease.Optimizing biological therapy in Crohn's disease.Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence.Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease.Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
P2860
Q26745721-5BA185E1-5166-430B-8271-C39B563E0719Q26996946-4898F4F8-0419-4BCB-AE36-AFC4A2F3C845Q33646452-55C02082-1C67-4930-AFEB-91A1CDBADDF5Q36089928-88C8EB6E-62C9-4413-A477-9581DF7C8BC0Q37662498-B26DD8CA-B797-4193-B5D7-4D87C19F1909Q38365848-1C384A96-4F7D-4FB3-985B-6FAB15A63A3EQ38608158-36E0A865-2CEA-4F46-A204-178F9CFB1E65Q38723456-5AFC5B9A-31F3-45A3-8B4F-E629E15463A1Q38919270-EC3044E1-6803-417F-8FA0-CCF064C9D997Q39353122-D68238D4-B3D0-4CB6-A2C0-F724C65552C2Q39442118-988E8244-DA8E-4569-BA33-59FFC7A7BDC6Q40070921-A34B35E8-79C1-410C-AC53-869C8615AE5FQ41122444-BB64F810-10A7-4FE0-B20A-87CFCD3AF451Q42151036-3A3B9BE8-8B3C-422B-BDB5-122E27BEE0D9Q47138621-AA18063C-C317-425B-8339-10046B50DA27Q47192581-7394737A-8B94-44D7-837D-FBB53FD40953Q47703013-DFE021FC-B027-4B2B-B2C7-46A3B9B4678DQ48223482-B9FF5356-CCDD-4AFC-98B0-CD2401F47CAEQ49500732-5FBE2C8B-E9F1-4FB9-A2C6-244D5BF03A18Q51290578-4F407FD3-ACB9-4732-A865-01C2607AAD70Q51353980-A7E2BAF1-D2C4-4591-A2FE-B046CD4868B8
P2860
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@ast
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@en
type
label
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@ast
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@en
prefLabel
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@ast
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@en
P2093
P2860
P50
P1476
Adalimumab monotherapy versus ...... atic review and meta-analysis.
@en
P2093
Alain Bitton
Ernest G Seidman
Mohammad Yaghoobi
Shomron Ben-Horin
Talal Al-Taweel
Waqqas Afif
P2860
P304
P356
10.1016/J.CROHNS.2014.07.003
P577
2014-07-25T00:00:00Z